News After FDA snub, DBV charts a new course for Viaskin peanut It’s been more than three years since DBV Technologies’ peanuty allergy therapy was
News NICE backs Aimmune's peanut allergy drug Palforzia for child... Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla
News DBV craters on FDA’s peanut allergy immunotherapy rejection DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
